Recombinant human IL-7
-
Cat.code:
rcyc-hil7
- Documents
ABOUT
Human IL-7 protein - Mammalian cell-expressed, tag-free, carrier-free
Recombinant human IL-7 is a high-quality and biologically active cytokine, validated using proprietary IL-7 reporter cells. This T-cell-mediating cytokine of the γc superfamily is produced in CHO cells to ensure protein glycosylation and bona fide 3D structure.
Recombinant human IL-7 can be used together with HEK-Blue™ IL-7 cells for the screening of inhibitory molecules, targeting the cytokine and not the IL-7 receptor (see figures).
Key features
- Each lot is validated using HEK-Blue™ IL-7 cells
- Endotoxin < 0.1 EU/µg
- 0.2 µm sterile-filtered
Applications
- T cell and NK cell activation and propagation
- IL-7 detection and quantification assays (positive control)
- Screening and release assays for antibodies blocking IL-7 signaling
- Screening and release assays for engineered IL-7 proteins
Interleukin 7 (IL-7) is a hematopoietic growth factor that is critical for T and B cell differentiation, proliferation, and survival. It is extensively studied as an adjuvant for cancer vaccines and for its role in CAR T cell expansion. IL-7 has also been described in a variety of applications, such as T cell activation, T cell priming, and differentiation.
All InvivoGen products are for internal research use only, and not for human or veterinary use.
SPECIFICATIONS
Specifications
P13232
> 1 x 108 IU/mg
Note: Please refer to the corresponding Certificate of Analysis (CoA) for the exact value. Each lot is tested with the reference standard for human IL-7 (NIBSC code 90/530) for reproducible cell culture conditions without the need for time-consuming lot-to-lot testing.
100 μg/ml in water
Phosphate buffer saline (pH 7.4), 5% saccharose
0.2 µm filtration
The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK‑Blue™ TLR4 cells.
Cellular assays (tested), Cell culture (T cell activation and expansion), ELISA
Each lot is functionally tested and validated.
CONTENTS
Contents
-
Product:Recombinant human IL-7
-
Cat code:rcyc-hil7
-
Quantity:10 µg
1.5 ml endotoxin-free water
Shipping & Storage
- Shipping method: Room temperature
- -20 °C
- Avoid repeated freeze-thaw cycles
Storage:
Caution:
Details
Interleukin 7 Signaling
Interleukin 7 (IL-7) is a secreted cytokine that plays an essential role in B cell and T cell development and function [1]. IL-7 signals through the heterodimeric cell surface IL-7 receptor (IL-7R) consisting of IL-7Rα (also called CD127) and IL-2Rγ (also called the common γ-chain or CD132). The binding of IL-7 to its receptor triggers three main signaling pathways: JAK/STAT, PI3K, and MAPK/ERK [1‑3]. Of note, IL-7R-mediated signaling triggers proliferative and anti‑apoptotic signals mainly by activating the JAK/STAT pathway [1-3]. IL-7/IL-7R signaling, which regulates lymphocyte growth and survival, has been implicated in the development of malignancies and autoimmune diseases [1-4].
IL-7 therapeutic targeting
The IL-7 cytokine, together with IL-2 and IL-15, is currently under investigation for application in ex vivo T cell expansion. These cytokines are used in different concentrations and combinations to improve cell viability, proliferation, and differentiation in CAR T cell culture [5]. Given the pleiotropic and robust biological effects of IL-7, especially its role in the survival, development, proliferation, and even maintenance of memory of T cells, several research teams apply IL-7 as a molecular adjuvant to strengthen the immunogenicity of cancer vaccines, as well as to maintain a long-term memory response against cancers [6].
References:
1. Lin J. et al., 2017. The role of IL-7 in Immunity and Cancer. Anticancer Res. 37(3):963-7.
2. Ribeir D. et al., 2018. STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells. Blood Adv. 2(17):2199-213.
3. Mackall C.L. et al., 2011. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol. 11(5):330-42.
4. Barata J.T. et al., 2019. Flip the coin: IL-7 and IL-7R in health and disease. Nat Immunol. 20(12):1584-93.
5. Sudarsanam H, et al., 2022. Influence of Culture Conditions on Ex Vivo Expansion of T Lymphocytes and Their Function for Therapy: Current Insights and Open Questions. Front Bioeng Biotechnol.;10:886637
6. Zhao Y, et al., 2022. IL-7: A promising adjuvant ensuring effective T cell responses and memory in combination with cancer vaccines? Front Immunol.;13:1022808.
DOCUMENTS
Documents
Technical Data Sheet
Validation Data Sheet
Safety Data Sheet
Certificate of analysis
Need a CoA ?
